UK Markets close in 3 mins
  • FTSE 100

    7,384.85
    +82.11 (+1.12%)
     
  • FTSE 250

    19,831.85
    +142.83 (+0.73%)
     
  • AIM

    957.00
    +9.83 (+1.04%)
     
  • GBP/EUR

    1.1813
    +0.0031 (+0.26%)
     
  • GBP/USD

    1.2460
    -0.0015 (-0.1221%)
     
  • BTC-GBP

    23,503.66
    -742.54 (-3.06%)
     
  • CMC Crypto 200

    652.11
    -21.26 (-3.16%)
     
  • S&P 500

    3,870.05
    -30.74 (-0.79%)
     
  • DOW

    31,037.68
    -215.45 (-0.69%)
     
  • CRUDE OIL

    112.77
    +0.56 (+0.50%)
     
  • GOLD FUTURES

    1,843.80
    +2.60 (+0.14%)
     
  • NIKKEI 225

    26,739.03
    +336.19 (+1.27%)
     
  • HANG SENG

    20,717.24
    +596.56 (+2.96%)
     
  • DAX

    13,960.78
    +78.48 (+0.57%)
     
  • CAC 40

    6,274.16
    +1.45 (+0.02%)
     

BB Biotech AG publishes its interim report

  • Oops!
    Something went wrong.
    Please try again later.
·2-min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

BB BIOTECH AG / Key word(s): Interim Report
BB Biotech AG publishes its interim report

22-Apr-2022 / 07:00 CET/CEST
Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

Ad hoc announcement pursuant to Art. 53 of the SIX Listing Rules
April 22, 2022

BB Biotech AG publishes its interim report

BB Biotech AG (ISIN CH0038389992) today published its interim report as at March 31, 2022, which covers the results of its business activities for the first three months of 2022.

Based on the consolidated accounts of BB Biotech AG, net loss for the period ended March 31, 2022 amounted to CHF 300 mn (profit of CHF 221 mn in the same period 2021). For an investment company, the results reflect the share price development of the companies held in the portfolio.

The interim report as at March 31, 2022 is available under report.bbbiotech.ch/Q122 or www.bbbiotech.com.


For further information:

Media Relations
Bellevue Asset Management AG, Seestrasse 16, 8700 Küsnacht, Switzerland, tel. +41 44 267 67 00
Tanja Chicherio, tch@bellevue.ch

www.bbbiotech.com

Company profile

BB Biotech AG is an investment company with its registered office in Schaffhausen/Switzerland and listed on the Swiss, German and Italian stock exchanges. It has invested in innovative drug developers headquartered primarily in the US and Western Europe. BB Biotech is one of the world's largest investors in this sector. BB Biotech relies on the long-standing experience of its distinguished Board of Directors and the investment research skills of the experienced investment management team of Bellevue Asset Management AG when making its investment decisions.

22-Apr-2022 CET/CEST The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de

Language:

English

Company:

BB BIOTECH AG

Schwertstrasse 6

8200 Schaffhausen

Switzerland

Phone:

+41 52 624 08 45

E-mail:

info@bbbiotech.com

Internet:

www.bbbiotech.ch

ISIN:

CH0038389992

WKN:

A0NFN3

Listed:

Regulated Market in Frankfurt (Prime Standard); Mailand, SIX

EQS News ID:

1331939


 

End of Announcement

DGAP News Service

show this
show this
Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting